Efavirenz-Loaded Polymeric Micelles for Pediatric Anti-HIV Pharmacotherapy with Significantly Higher Oral Bioavailability

• Panel of clinical practices for treatment of HIV infection. Guidelines for the use of antiretroviral agents to treat HIV infection in pediatric patients. Pan. Am. J. Public Health10, 426–435 (2001).
   Google Scholar
• Shah CA : Adherence to high activity antiretroviral therapy (HAART) in pediatric patients infected with HIV: issues and interventions.Indian J. Pediatr.74, 55–60 (2007).
   PubMed Web of Science ®Google Scholar
• Andrews L , FriedlandG: Progress in the HIV therapeutics and the challenges of adherence to antiretroviral therapy.Inf. Dis. Clin. N. Amer.14, 1–26 (2000).
   PubMed Web of Science ®Google Scholar
• Giaquinto C , MorelliE, FregoneseFet al.: Current and future antiretroviral treatment options in pediatric HIV infection 1.Clin. Drug Invest.28, 375–397 (2008).
   PubMed Web of Science ®Google Scholar
• Brown E : In: Antiretroviral Therapy in Children, HIV/AIDS Primary Care Guide. Chapter 30, AIDS Education & Training Centers National Resource Center, 419 (2007).
   Google Scholar
• Standing JF , TuleuC: Pediatric formulations – getting to the heart of the problem.Int. J. Pharm.300, 56–66 (2005).
   PubMed Web of Science ®Google Scholar
• Conroy S : Extemporaneous (magistral) preparation of oral medicines for children in European hospitals.Acta Paediatr.92, 408–411 (2003).
   PubMed Web of Science ®Google Scholar
• Choonara I , ConroyS: Unlicensed and off-label drug use in children: implications for safety.Drug Saf.25, 1–5 (2002).
   PubMed Web of Science ®Google Scholar
• Nunn T , WilliamsJ: Formulation of medicines for children.Br. J. Clin. Pharmacol.59, 674–676 (2005).
   PubMed Web of Science ®Google Scholar
• Kairuz TE , GargiuloD, BuntCet al.: Quality, safety and efficacy in the ‘off-label’ use of medicines.Curr. Drug Saf.2, 89–95 (2007).
   PubMedGoogle Scholar
• Committee on Pediatric AIDS. Section on international child health. increasing antiretroviral drug access for children with HIV infection. Pediatrics119, 838–845 (2007).
   PubMed Web of Science ®Google Scholar
• Lindenberg M , KoppS, DressmanJB: Classification of orally administered drugs on the World Health Organization Model List of Essential Medicines according to the biopharmaceutics classification system.Eur. J. Pharm. Biopharm.58, 265–278 (2004).
   PubMed Web of Science ®Google Scholar
• Gazzard B : British HIV Association (BHIVA) guidelines for the treatment of HIV infected adults with antiretroviral therapy.HIV Med.7, 487–496 (2006).
   PubMed Web of Science ®Google Scholar
• Barrueco N , CastilloI, AisAet al.: Program of pharmaceutic attention to pediatric patients in antiretroviral therapy.Farm. Hosp.29, 367–374 (2005).
   PubMedGoogle Scholar
• Wintergerst U , HoffmannF, JanssonAet al.: Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children.J. Antimicrob. Chemother.61, 1336–1339 (2008).
   PubMed Web of Science ®Google Scholar
• Rabel SR , SunS, MaurinMB: Electronic and resonance effects on the ionization of structural analogues of efavirenz.AAPS PharmSciTech3, 28 (2001).
   PubMedGoogle Scholar
• Gao JZ h, Hussain MA, Motheram R et al.: Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz). J. Pharm. Sci.96, 2970–2977 (2007).
   PubMed Web of Science ®Google Scholar
• Csajka C , MarzolliniC, FattingerKet al.: Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.Clin. Pharm. Ther.73, 20–30 (2003).
   PubMed Web of Science ®Google Scholar
• Aarnoutse R , SchapiroJM, BouchrCABet al.: Therapeutic drug monitoring.Drugs63, 741–753 (2003).
   PubMed Web of Science ®Google Scholar
• Amidon GL , LennernäsH, ShahVPet al.: A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.Pharm. Res.12, 413–420 (1995).
   PubMed Web of Science ®Google Scholar
• Lipinski C : Poor aqueous solubility – an industry wide problem in drug discovery.Am. Pharm. Rev.5, 82–85 (2002).
   Google Scholar
• Ellis JM , RossJW, ColemanCIet al.: Fosamprenavir: a novel protease inhibitor and prodrug of amprenavir.Formulary39, 151–160 (2004).
   Google Scholar
• Yu L , BridgersA, PolliJet al.: Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability.Pharm. Res.16, 1812–1817 (1999).
   PubMed Web of Science ®Google Scholar
• Starr SE , FletcherCV, SpectorSAet al.: Efavirenz liquid formulation in human immunodeficiency virus-infected children.Pediatr. Infect. Dis. J.21, 659–663 (2002).
   PubMed Web of Science ®Google Scholar
• Bahal SM , RomanskyJM, AlvarezFJ: Medium chain triglycerides as vehicle for palatable oral liquids.Pharm. Dev. Technol.8, 111–115 (2003).
   PubMed Web of Science ®Google Scholar
• Dutta T , AgasheHB, GargMet al.: Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro.J. Drug Target15, 89–98 (2007).
   PubMed Web of Science ®Google Scholar
• Dutta T , GargM, JainNK: Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro.Eur. J. Pharm. Sci.34, 181–189 (2008).
   PubMed Web of Science ®Google Scholar
• Sathigar S , ChadhaG, Lee Y-HP et al.: Physicochemical characterization of efavirenz–cyclodextrin inclusion complexes. AAPS PharmSciTech10, 81–87 (2009).
   PubMed Web of Science ®Google Scholar
• Shown I , MurthyCN: Synthesis and characterization of linear water-soluble γ-cyclodextrin based polymers as drug carrier systems.Supramol. Chem.20, 573–578 (2008).
   Web of Science ®Google Scholar
• Smart T : Children with HIV are being left behind in the rollout of antiretroviral therapy, HIV & AIDS. Treatment in Practice HATIP #40, 28 January 2005.
   Google Scholar
• Sosnik A , ChiappettaDA, CarcabosoAM: Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead.J. Control. Release138, 2–15 (2009).
   PubMed Web of Science ®Google Scholar
• Chiappetta DA , CarcabosoAM, BregniCet al.: Indinavir-loaded pH-sensitive microparticles for taste masking: toward extemporaneous pediatric anti-HIV/AIDS liquid formulations with improved patient compliance.AAPS PharmSciTech10, 1–6 (2009).
   PubMed Web of Science ®Google Scholar
• Sosnik A , CarcabosoAM, ChiappettaDA: Polymeric nanocarriers: new endeavors for the optimization of the technological aspects of drug.Recent Pat. Biomed. Eng.1, 43–59 (2008).
   Google Scholar
• Chiappetta DA , SosnikA: Poly(ethylene oxide)–poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs.Eur. J. Pharm. Biopharm.66, 303–317 (2007).
   PubMed Web of Science ®Google Scholar
• Chiappetta DA , DegrossiJ, TevesSet al.: Triclosan-loaded poloxamine micelles for enhanced antibacterial activity against biofilm.Eur. J. Pharm. Biopharm.69, 535–545 (2008).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Lopez J , Alvarez-LorenzoC, TaboadaPet al.: Self-associative behavior and drug solubilizing ability of poloxamine (Tetronic) block copolymers.Langmuir24, 10688–10697 (2008).
   PubMed Web of Science ®Google Scholar
• Reeve L . In: Handbook of Biodegradble Polymers (Drug Targeting and Delivery, Volume 7) (1st Edition). Domb A, Kost Y, Wiseman D (Eds). Harwood Academic Publishers, London, UK (1997).
   Google Scholar
• Bromberg LE , RonES: Temperature-responsive gels and thermogelling polymer matrices for protein and peptide delivery.Adv. Drug Del. Rev.31, 197–221 (1998).
   PubMed Web of Science ®Google Scholar
• Subbaraman LN , BayerS, Glasier M-A et al.: Rewetting drops containing surface active agents improve the clinical performance of silicone hydrogel contact lenses. Opt. Vis. Sci.83, 143–151 (2006).
   PubMed Web of Science ®Google Scholar
• de Aquino Ribeiro JA , Moreira de Campos LM, Alves RJ et al.: Efavirenz related compounds preparation by hydrolysis procedure: setting reference standards for chromatographic purity analysis. J. Pharm. Biomed. Anal.43, 298–303 (2007).
   PubMed Web of Science ®Google Scholar
• Sankar DG , KumarJMR, ReddyMVVN: UV spectrophotometric methods for the determination of saquinavir mesylate and efavirenz.Asian J. Chem.15, 1856–1858 (2003).
   Google Scholar
• Aimone LD : Overview of pharmacokinetics.Curr. Protocols Pharmacol. Suppl. 30 Unit 7.1, 1–26 (2005).
   PubMedGoogle Scholar
• Maurin MB , RoweSM, BlomKet al.: Kinetics and mechanism of hydrolysis of efavirenz.Pharm. Res.19, 517–521 (2002).
   PubMed Web of Science ®Google Scholar
• Dong J , ArmstrongJ, ChowdryBZet al.: Thermodynamic modelling of the effect of pH upon aggregation transitions in aqueous solutions of poloxamine T701.Therm. Acta417, 201–206 (2004).
   Web of Science ®Google Scholar
• Riess G : Micellization of block copolymers.Prog. Polym. Sci.28, 1107–1170 (2003).
   Web of Science ®Google Scholar
• Allen C , MaysingerD, EisenbergA: Nano-engineering block copolymer aggregates for drug delivery.Colloids Surf. B16, 3–27 (1999).
   Web of Science ®Google Scholar
• Xu RL , WinnikMA, HallettFRet al.: Light-scattering study of the association behavior of styrene–ethylene oxide block copolymers in aqueous solution.Macromolecules24, 87–93 (1991).
   Web of Science ®Google Scholar
• Croy SR , KwonGS: The effects of Pluronic block copolymers on the aggregation state of nystatin.J. Control. Release95, 161–171 (2004).
   PubMed Web of Science ®Google Scholar
• Wang L , ZhangX, PooyanSet al.: Optimizing size and copy number for PEG–fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarrier uptake by macrophagesBioconjug. Chem.19, 28–38 (2008).
   PubMed Web of Science ®Google Scholar
• Alexandridis P , HolzwarthJF, HattonTA: Micellization of poly(ethylene oxide)–poly(propylene oxide)–poly(ethylene oxide) triblock copolymers in aqueous solutions: Thermodynamics of polymer association.Macromolecules27, 2414–2425 (1994).
   Web of Science ®Google Scholar
• Kwon GS : Polymeric micelles for delivery of poorly water-soluble compounds.Crit. Rev. Therap. Drug Carrier Syst.20, 357–403 (2003).
   PubMed Web of Science ®Google Scholar
• Balani SK , KauffmanLR, DelunaFAet al.: Nonlinear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys.Drug Metab. Disp.27, 41–45 (1999).
   PubMed Web of Science ®Google Scholar
• Chiappetta D , HöchtC, TairaC, SosnikA: Efavirenz-loaded PEO-PPO polymeric micelles enhance the oral bioavailaibility in the anti-HIV pharmacotherapy. Presented at: The Annual Congress of the Argentine Society of Experimental Pharmacology (SAFE). Rosario, Argentina, 23–27 November 2009.
   Google Scholar
• Kibbe AH : In: Handbook of Pharmaceutical Excipients. American Pharmaceutical Association, Washington DC, USA 386–388 (2000).
   Google Scholar
• Sosnik A , AmijiM: Nanotechnology solutions for infectious diseases in developing nations.Adv. Drug Del. Rev. (2009) (Epub ahead of print).
   Web of Science ®Google Scholar
• Nakashima K , AnzaiT, FujimotoY: Fluorescence studies on the properties of a Pluronic F68 micelle.Langmuir10, 658–661 (1994).
   Web of Science ®Google Scholar
• Alexandridis P , HattonTA: Poly(ethylene oxide)–poly(propylene oxide)–poly(ethylene oxide) block copolymer surfactants in aqueous solutions and interfaces: thermodynamics, structure, dynamics and modeling.Colloids Surf. A96, 1–46 (1995).
   Web of Science ®Google Scholar
• Fernandez-Tarrio M , YañezF, ImmesoeteKet al.: Pluronic and Tetronic copolymers with polyglycolyzed oils as self-emulsifying drug delivery systems.AAPS PharmSciTech9, 471–479 (2008).
   PubMed Web of Science ®Google Scholar

Websites

• AIDS epidemic update 2007, WHO. www.who.int/hiv/epiupdates/en/index.html
   Google Scholar
• UNAIDS/WHO AIDS Epidemic. www.unaids.org/en/HIV
   Google Scholar
• Medecins sans Frontieres, Press release. www.msf.org
   Google Scholar
• Children and HIV, AIDS Infonet, Fact sheet 612 (December 2007). www.thebody.com/content/treat/art6014.html
   Google Scholar
• European Commission-Enterprise and Industry. Medicines for Children, 2008. http://ec.europa.eu/enterprise/pharmaceuticals/pediatrics/index.htm
   Google Scholar
• WHO/Make medicines child size. www.who.int/childmedicines/en
   Google Scholar